purchased from the American Type Culture Collection (ATCC; Manassas, VA). Cells
were cultured in EMEM (ATCC) supplemented with 10% fetal bovine serum
(Life Technologies; Carlsbad, CA) in 25 cm2 polystyrene flasks placed
in a Hera Cell 5% CO2 37°C incubator (ThermoFisher
Scientific; Waltham, MA). Routine passage was carried out every 2 or 3 days.
About 2 × 105 HepG2 cells were seeded per 6-cm plate
and serum-starved for 24 h before the following treatments: 50, 100 or 200
μg/ml human LDL-cholesterol (LDL-C) (Kalen Biomedical; Montgomery Vlg,
MD); 10, 30 or 90 μM simvastatin (Sigma; St Louis, MO); 100 nM insulin
(Sigma); 30 nM glucose (Sigma); 5 μM Bay-11 (Cayman; Ann Arbor, MI); 200
μM fatty acids conjugated with 0.2% BSA (30 mM) in 1%
ethanol. We treated HepG2 cells for 24 h with palmitic acid (Sigma), palmitoleic
acid, stearic acid, oleic acid, linoleic acid, linolenic acid, and
eicosapentaenoic acid (Cayman).